Skip to main content
Top
Published in: International Journal of Hematology 4/2018

01-10-2018 | Original Article

Immuno-suppressive function of nucleus-transducible BAF57-ΔPH in T cell activation via degradation of endogenous BAF57

Authors: Jae-Seung Moon, Hong-Jai Lee, Chun-Chang Ho, Jin-Su Shin, Sankar Ghosh, Jung-Ho Kim, Sang-Kyou Lee

Published in: International Journal of Hematology | Issue 4/2018

Login to get access

Abstract

The BAF57 subunit, an indispensable member of the BAF complex, is functionally implicated in apoptosis, cell cycle, and T cell development through chromosomal remodeling. However, the precise roles of BAF57 in the T cell receptor (TcR)-mediated signaling pathway have not been elucidated. In this study, a nucleus-transducible form of BAF57, absent the proline-rich and HMG domains (ntBAF57-ΔPH), was generated to interfere with the interaction between BAF57 and its binding protein, BAF155. ntBAF57-ΔPH was effectively delivered into mouse CD4+ T cells in a dose- and time-dependent manner, without cellular toxicity. Inhibition of T cell activation by ntBAF57-ΔPH was mediated by its disruption of the interaction between BAF155 and BAF57, leading to the degradation of endogenous BAF57 and BAF155. This phenomenon led to alterations in gene expression similar to those associated with Ciclosporin A treatment. In vivo administration of ntBAF57-ΔPH enhanced survival rate of sepsis-induced mice and reduced the LPS-induced secretion of pro-inflammatory cytokines and the expression of endogenous BAF57. These results reveal a novel function of BAF57 as an essential regulator of T cell activation. ntBAF57-ΔPH represents a novel immune-suppressive drug candidate with potential uses in the treatment of autoimmunity and graft rejection.
Appendix
Available only for authorised users
Literature
2.
go back to reference Zhao K, Wang W, Rando OJ, Xue Y, Swiderek K, Kuo A, et al. Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. Cell. 1998;95(5):625–36.CrossRefPubMed Zhao K, Wang W, Rando OJ, Xue Y, Swiderek K, Kuo A, et al. Rapid and phosphoinositol-dependent binding of the SWI/SNF-like BAF complex to chromatin after T lymphocyte receptor signaling. Cell. 1998;95(5):625–36.CrossRefPubMed
3.
go back to reference Gebuhr TC, Kovalev GI, Bultman S, Godfrey V, Su L, Magnuson T. The role of Brg1, a catalytic subunit of mammalian chromatin-remodeling complexes, in T cell development. J Exp Med. 2003;198(12):1937–49.CrossRefPubMedPubMedCentral Gebuhr TC, Kovalev GI, Bultman S, Godfrey V, Su L, Magnuson T. The role of Brg1, a catalytic subunit of mammalian chromatin-remodeling complexes, in T cell development. J Exp Med. 2003;198(12):1937–49.CrossRefPubMedPubMedCentral
4.
go back to reference Chi TH, Wan M, Zhao K, Taniuchi I, Chen L, Littman DR, et al. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature. 2002;418(6894):195–99.CrossRefPubMed Chi TH, Wan M, Zhao K, Taniuchi I, Chen L, Littman DR, et al. Reciprocal regulation of CD4/CD8 expression by SWI/SNF-like BAF complexes. Nature. 2002;418(6894):195–99.CrossRefPubMed
5.
go back to reference Brettingham-Moore KH, Sprod O, Chen X, Oakford P, Shannon MF, Holloway AF. Determinants of a transcriptionally competent environment at the GM-CSF promoter. Nucleic Acids Res. 2008;36(8):2639–53.CrossRefPubMedPubMedCentral Brettingham-Moore KH, Sprod O, Chen X, Oakford P, Shannon MF, Holloway AF. Determinants of a transcriptionally competent environment at the GM-CSF promoter. Nucleic Acids Res. 2008;36(8):2639–53.CrossRefPubMedPubMedCentral
6.
7.
go back to reference Jeong SM, Lee C, Lee SK, Kim J, Seong RH. The SWI/SNF chromatin-remodeling complex modulates peripheral T cell activation and proliferation by controlling AP-1 expression. J Biol Chem. 2010;285(4):2340–50.CrossRefPubMed Jeong SM, Lee C, Lee SK, Kim J, Seong RH. The SWI/SNF chromatin-remodeling complex modulates peripheral T cell activation and proliferation by controlling AP-1 expression. J Biol Chem. 2010;285(4):2340–50.CrossRefPubMed
8.
go back to reference De S, Wurster AL, Precht P, Wood WH, Becker KG, Pazin MJ. Dynamic BRG1 recruitment during T helper differentiation and activation reveals distal regulatory elements. Mol Cell Biol. 2011;31(7):1512–27.CrossRefPubMedPubMedCentral De S, Wurster AL, Precht P, Wood WH, Becker KG, Pazin MJ. Dynamic BRG1 recruitment during T helper differentiation and activation reveals distal regulatory elements. Mol Cell Biol. 2011;31(7):1512–27.CrossRefPubMedPubMedCentral
9.
go back to reference Chen J, Archer TK. Regulating SWI/SNF subunit levels via protein–protein interactions and proteasomal degradation: BAF155 and BAF170 limit expression of BAF57. Mol Cell Biol. 2005;25(20):9016–27.CrossRefPubMedPubMedCentral Chen J, Archer TK. Regulating SWI/SNF subunit levels via protein–protein interactions and proteasomal degradation: BAF155 and BAF170 limit expression of BAF57. Mol Cell Biol. 2005;25(20):9016–27.CrossRefPubMedPubMedCentral
10.
go back to reference Choi J-M, Ahn M-H, Chae W-J, Jung Y-G, Park J-C, Song H-M, et al. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med. 2006;12(5):574–9.CrossRefPubMed Choi J-M, Ahn M-H, Chae W-J, Jung Y-G, Park J-C, Song H-M, et al. Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med. 2006;12(5):574–9.CrossRefPubMed
11.
go back to reference Park T-Y, Park S-D, Cho J-Y, Moon J-S, Kim N-Y, Park K, et al. RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells. Proc Natl Acad Sci USA. 2014;111(52):18673–78.CrossRefPubMed Park T-Y, Park S-D, Cho J-Y, Moon J-S, Kim N-Y, Park K, et al. RORγt-specific transcriptional interactomic inhibition suppresses autoimmunity associated with TH17 cells. Proc Natl Acad Sci USA. 2014;111(52):18673–78.CrossRefPubMed
12.
go back to reference Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature. 1994;369(6480):497–502.CrossRefPubMed Northrop JP, Ho SN, Chen L, Thomas DJ, Timmerman LA, Nolan GP, et al. NF-AT components define a family of transcription factors targeted in T-cell activation. Nature. 1994;369(6480):497–502.CrossRefPubMed
13.
go back to reference Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14(1):649–81.CrossRefPubMed Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol. 1996;14(1):649–81.CrossRefPubMed
14.
go back to reference Rincon M, Flavell R. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 1994;13(18):4370–81.CrossRefPubMedPubMedCentral Rincon M, Flavell R. AP-1 transcriptional activity requires both T-cell receptor-mediated and co-stimulatory signals in primary T lymphocytes. EMBO J. 1994;13(18):4370–81.CrossRefPubMedPubMedCentral
15.
go back to reference Reynolds JM, Martinez GJ, Chung Y, Dong C. Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci USA. 2012;109(32):13064–69.CrossRefPubMed Reynolds JM, Martinez GJ, Chung Y, Dong C. Toll-like receptor 4 signaling in T cells promotes autoimmune inflammation. Proc Natl Acad Sci USA. 2012;109(32):13064–69.CrossRefPubMed
Metadata
Title
Immuno-suppressive function of nucleus-transducible BAF57-ΔPH in T cell activation via degradation of endogenous BAF57
Authors
Jae-Seung Moon
Hong-Jai Lee
Chun-Chang Ho
Jin-Su Shin
Sankar Ghosh
Jung-Ho Kim
Sang-Kyou Lee
Publication date
01-10-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2491-6

Other articles of this Issue 4/2018

International Journal of Hematology 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine